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Abstract Upon the introduction of extensive sampling
protocols of sentinel node biopsies, pathologists are
increasingly confronted with small melanoma metastases.
Using conventional histology, it proves sometimes diffi-
cult or impossible to differentiate small melanoma
metastases from lymph-node nevi. Loss of the tumour
suppressor gene p16 has been shown to be associated with
tumour progression of melanoma. We investigated nevus
and melanoma cells for the presence of the product of the
gene p16, using immunohistochemistry. All nevus cells,
independent of their location (nodal or skin) displayed an
extensive nuclear and cytoplasmic staining for p16. In
contrast, all cells of melanoma metastases, except one
skin metastasis, lacked nuclear staining for p16. These
findings indicate that p16 is a reliable marker to
distinguish lymph-node nevi from melanoma metastasis.
Keywords Nodal nevus · Metastatic melanoma · Sentinel
lymph node · Tumour suppressor gene · p16
Introduction
The reliable differentiation between lymph-node nevus
and melanoma metastasis is sometimes difficult. The
recommended marker panel for diagnosis of melanoma
[S-100 protein, gp100 (HMB45), Melan-A/MART-1
(A103) and Tyrosinase (T311)] is not always useful to
reliably discriminate the two lesions [4]. However, this
differential diagnosis bears a particular importance in
sentinel lymph nodes, as the diagnosis of melanoma
metastasis leads to therapeutic lymph-node dissection.
The product of the p16/INK4a/CDKN2/MTS tumour
suppressor gene acts as a negative cell cycle regulator by
inhibiting G1 cyclin-dependent kinases, which are phos-
phorylating the retinoblastoma protein [10, 18]. P16 is
inactivated or lost in a wide range of human malignancies
[15], including familial melanoma [3]. In sporadic
melanoma, the results are still not conclusive [7, 8]. Loss
or inactivation of the p16 gene has been shown to be
associated with the progression of melanoma and other
tumours [9, 16].
The goal of this study was to test the p16 as a marker
to discriminate nodal nevi from melanoma metastases.
We investigated dermal and nodal nevi, melanoma
metastases of lymph nodes and other organs for loss of
p16 expression, using immunohistochemistry.
Materials and methods
Tissue samples
Formaldehyde-fixed and paraffin-embedded tissue specimens from
the archives of the Department of Pathology, University of Zrich
and of the Institute of Pathology, Kantonsspital Aarau (one sample)
were investigated. Tested for the presence of p16 product were 18
nodal nevi of 13 patients, 26 sentinel lymph-node metastases of 19
melanoma patients, 10 non-sentinel lymph-node melanoma metas-
tases of 10 patients and 13 organ metastases of melanoma of 12
patients. As lymph-node nevi are relatively uncommon [1, 17], and
in this study most of them were from melanoma patients, we
additionally tested 15 skin nevi (9 dermal, 5 compound and 1
junctional) of 9 patients. Haematoxylin and eosin-stained sections
of all samples were reviewed by one pathologist (D.M.). For
clinical data, see Table 1, Table 2 and Table 3.
Immunohistochemistry
A monoclonal primary antibody directed against an epitope of p16
(Neomarkers, Freemont, CA, USA) was used. The epitope of Ab-4
maps among amino acids 1–32 of the p16/INK4a protein.
Two-micron-thick sections of paraffin-embedded tissue were
collected onto Superfrost Plus slides (Menzel Glser, Germany) and
dewaxed in graded alcohols. Non-specific peroxidase activity was
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blocked with 3% hydrogen peroxide in phosphate buffer saline for
10 min. Microwave pre-treatment was performed for 10 min in
0.01 mol/l tri-natrium citrate puffer at pH 6.3. The sections were
incubated with p16 antibody (Clone 16P04; Neomarkers, Freemont,
CA, USA) at an antibody concentration of 40 mg/ml at room
temperature for 2 h. P16 detection was performed with “Elite”
universal detection kit (Vector, Peterborough, UK) and colour was
developed using diaminobenzidine. A dermal nevus, an oligoas-
trocytoma (G2, World Health Organization) and endocrine cells of
the pancreas were used as positive controls. Negative controls were
performed by replacing the specific antiserum with pure Tris saline.
We differentiated nuclear and cytoplasmic staining from
exclusive cytoplasmic staining. The extent of each staining was
recorded according to the following system: 0=no staining;
1+=<25% of cells positive; 2+=25–49% of cells positive; 3+=50–
74% of cells positive; 4+=>75% cells positive.
For Ki-67, HMB45 and S-100 protein, immunohistochemistry
was performed on paraffin sections of formalin-fixed tissues, using
a Ventana Benchmark automated staining system (Ventana Medical
Systems, Tucson, Arizona). For antigen retrieval, slides were
heated with cell conditioner 1 (mild protocol). Primary antibodies
(all from DakoCytomation, Glostrup, Denmark) against the
following antigens were applied: Ki-67 proliferation antigen (clone
Table 1 Lymph-node nevi. Nuc nuclear staining, CS cytoplasmic without nuclear staining, NP no proliferation
Patient
no.
Age
(years)/sex
Site of
node
Primary
tumor
Operation Size
(mm)
S-100 P HMB 45 P16 Nuc P16 CS MIB-1
1 49/Female Axilla Melanoma Node dissection 7 4+ 0 4+ 4+ NP
2 67/Male Neck Melanoma Node dissection 0.5 4+ 0 4+ 4+ *
3 30/Female Axilla Melanoma Sentinel node 0.4 4+ 0 3+ 3+ NP
4 57/Female Inguina Melanoma Sentinel node 0.5 4+ 0 4+ 4+ NP
5 66/Male Axilla Melanoma Sentinel node 2.5 4+ 0 3+ 3+ <0.2%
6a 61/Male Inguina Melanoma Sentinel node 5 4+ 0 3+ 3+ <0.3%
b Inguina Sentinel node 3 4+ 0 4+ 4+ <0.3%
c Inguina Node dissection 0.5 4+ 0 3+ 3+ NP
d Inguina Node dissection 2 4+ 0 3+ 3+ <0.3%
7a 63/Male Axilla Melanoma Sentinel node 0.5 4+ 0 4+ 4+ NP
b Axilla Sentinel node 0.3 4+ 0 4+ 4+ NP
8 67/Female Inguina No Femoral hernia 0.8 4+ 0 3+ 3+ <0.2%
9a 66/Female Axilla Breast cancer Node dissection 20 4+ 0 4+ 4+ NP
b Axilla Node dissection 2.5 4+ 0 4+ 4+ NP
10 20/Male Inguina Melanoma Sentinel node 0.1 4+ 0 4+ 4+ NP
11 50/Female Axilla Melanoma Sentinel node 2.5 4+ 0 4+ 4+ NP
12 61/Male Axilla Melanoma Sentinel node 0.2 4+ 0 4+ 4+ NP
13 60/Male Neck Melanoma Sentinel node 0.2 4+ 0 4+ 4+ NP
* On additional serial sections the lesion was no longer present
Table 2 Sentinel lymph-node metastases. Nuc nuclear staining, CS cytoplasmic without nuclear staining, NP no proliferation
Patient no. Age (years)/sex Site of node Size (mm) S-100 P HMB 45 P16 Nuc P16 CS MIB-1
1 57/Male Axilla 2.5 4+ 0 0 0 *
2 50/Male Infraclavicular 0.5 4+ 4+ 0 0 *
3 62/Male Ocipital 1 4+ 4+ 0 0 25–50%
4 68/Male Axilla 0.7 4+ 0 0 0 10–25%
5a 64/Male Axilla 1.4 4+ 1+ 0 3+ 10–25%
b Axilla 1.3 4+ 2+ 0 2+ 10–25%
6 61/Male Ocipital 2.5 4+ 2+ 0 2+ 6%
7 48/Female Axilla 1 4+ 4+ 0 0 25–50%
8 59/Male Inguina 8 4+ 4+ 0 3+ 25–50%
9 58/Male Inguina 0.6 4+ 2+ 0 0 10–25%
10a 68/Male Inguina 0.2 4+ 4+ 0 0 4%
b Inguina 1 4+ 4+ 0 3+ 25–50%
11a 64/Male Ellbow 1 4+ 0 0 0 10–25%
b Axilla 0.6 4+ 1+ 0 0 10–25%
12a 74/Female Inguina 0.8 4+ 1+ 0 0 10–25%
b Inguina 0.4 4+ 0 0 0 3%
13 63/Female Inguina 2 4+ 4+ 0 0 10–25%
14 60/Male Inguina 1 4+ 0 0 0 NP
15 22/Female Inguina 1.2 4+ 2+ 0 1+ *
16 59/Male Axilla 3.5 4+ 3+ 0 0 10–25%
17a 19/Female Ocipital 0.5 4+ 0 0 0 4%
b Ocipital 0.8 4+ 0 0 0 5%
18 61/Male Inguina 0.7 4+ 0 0 0 10–25%
19a 71/Male Axilla 0.7 4+ 1+ 0 0 10–25%
b Axilla 0.2 4+ 1+ 0 0 10–25%
c Axilla 0.1 4+ 1+ 0 0 10–25%
* On additional serial sections the lesion was no longer present
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MIB-1, dilution 1:20), melanosome antigen (clone HMB45,
dilution 1:50) and S-100 protein (rabbit affinity purified antibodies,
dilution 1:1000). Monoclonal mouse MIB-1 antibodies were
detected with the Ventana iVIEW DAB detection kit, yielding a
brown reaction product. Monoclonal mouse HMB45 and polyclonal
rabbit anti-S-100 antibodies were revealed with the Ventana-Red
enhanced detection kit (red reaction product). For HMB45, the
signal was enhanced with the Ventana amplification kit. Slides
were counterstained with haematoxylin. MIB-1 labelling of lymph-
node nevi and melanoma metastases was recorded as the ratio of
marked nuclei (cells) of the total number of cells per visual field.
Results
Clinical findings
The clinical findings in 13 patients (20–67 years old) with
nodal nevi, 22 patients (30–78 years old) with melanoma
metastasis and 19 patients (19–74 years old) with sentinel
node melanoma metastasis are listed in Table 1, Table 2
and Table 3. Nine nodal nevi were located in axillary
lymph nodes, seven in inguinal nodes and two in neck
nodes. Of the patients, 11 had undergone lymph-node
biopsies for cutaneous melanoma, 1 patient for breast
cancer and 1 for a femoral hernia. In all but one (patient
6) patient with nodal nevi, neither concomitant melanoma
metastasis nor clinical signs of metastasis were present
(mean clinical follow-up to 2 years). In nine patients (6–
68 years old), 9 of 15 skin nevi were dermal, 5 were
compound and 1 was junctional.
Histopathology
For a lesion to be accepted as lymph-node nevus,
aggregates of cytologically typical melanocytes must be
present in the lymph-node capsule and/or fibrous trabec-
ulae. Only three large nodal nevi (patients 6a, b, d) and
one small nodal nevus (0.4 mm, patient 3, Fig. 1) did not
fulfil these conditions, as they were partially localised
within the lymph node and were in direct contact with its
parenchyma. The benign nature of these four lesions was
confirmed by the presence of cytologically typical
melanocytes, a very low (<0.3%) proliferation index in
combination with a clear-cut nuclear staining for p16.
Patient 6 suffered from an additional sentinel node
micrometastasis (registered as patient 18) displaying a
different, malignant (atypical) morphology of the mela-
nocytes, a distinctly higher proliferation index (18%) and
an absent staining for p16.
The histological findings are illustrated in Fig. 1,
Fig. 2, Fig. 3 and Fig. 4 and listed in Table 1, Table 2 and
Table 3. The size of nodal nevi (measured as the single
greatest dimension) ranged from 0.1 mm to 20 mm with
an average of 2.7 mm. Of 18 nodal nevi, 11 were small
(maximum 2 mm). The size of melanoma metastasis in
sentinel lymph nodes ranged from 0.1 mm to 8 mm with
an average of 1.3 mm. The diameter of 21 of 26 sentinel
node metastases measured less than 2 mm. Diagnostic
difficulties occurred in two lymph-node metastases, as
they were partially localised within the capsule and were
almost lacking HMB 45 reactivity (patients 5a and 12b).
Melanoma micrometastasis in the lymph-node parenchy-
ma displaying an identical morphology and immunohis-
tochemistry confirmed the metastatic origin of these cells
(Fig. 2).
Table 3 Melanoma metastases:
node dissection and organ me-
tastasis. Nuc nuclear staining,
CS cytoplasmic without nuclear
staining
Patient
no.
Age
(years)/sex
Site S-100 P HMB 45 P 16 Nuc P16 CS MIB-1
1 77/Male Neck* 4+ 0 0 4+ 10–25%
2 54/Female Infraclavicular* 4+ 2+ 0 0 5%
3 78/Male Inguinal* 4+ 1+ 0 0 25–50%
4 40/Male Neck* 4+ 0 0 4+ 25–50%
5 59/Female Neck* 4+ 4+ 0 0 25–50%
6 75/Male Axilla* 4+ 3+ 0 0 10–25%
7 47/Female Axilla* 4+ 3+ 0 0 8%
8 73/Male Axilla* 4+ 0 0 3+ 25–50%
9 36/Male Axilla* 4+ 1+ 0 0 25–50%
10 56/Female Retroauricular* 4+ 2+ 0 0 10–25%
11 30/Female Liver 4+ 2+ 0 1+ 10–25%
12 67/Male Skin (thorax) 3+ 3+ 0 0 10–25%
13 47/Male Subcutis (face) 4+ 0 0 0 10–25%
14 59/Male Small bowel 4+ 1+ 0 4+ 10–25%
15 69/Male Skin (inguina) 4+ 4+ 1+ 3+ 25–50%
16 60/Male Parotid gland 4+ 0 0 0 10–25%
17 59/Male Soft tissue axilla 4+ 1+ 0 0 25–50%
18 58/Male Soft tissue axilla 4+ 1+ 0 0 10–25%
Soft tissue axilla 4+ 2+ 0 0 10–25%
19 56/Male Skin (thorax) 4+ 2+ 0 4+ 25–50%
20 69/Male Subcutis (inguina) 4+ 4+ 0 0 4%
21 47/Female Soft tissue axilla 4+ 4+ 0 0 10–25%
22 63/Male Skin 4+ 0 0 0 25–50%
* Node dissection
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Immunohistochemistry
We found two types of immunoreactions of p16 in
melanocytes: nuclear and cytoplasmic staining and
diffuse cytoplasmic staining with absence of nuclear
staining. All 33 nevi (18 nodal and 15 dermal) displayed
an extensive and intense nuclear and cytoplasmic stain-
ing, whereas nuclear staining was absent in 48 of 49
melanoma metastases (26 sentinel nodes, 10 non-sentinel
nodes and 13 organ metastases) (Fig. 3). Only one
inguinal skin metastasis displayed a focal weak (1+)
nuclear positivity. In contrast, melanoma metastases in 6
of 26 sentinel nodes, in 3 of 10 non-sentinel nodes and in
4 of 13 organ metastases displayed an exclusive cyto-
plasmic staining (Fig. 3).
Controls
All positive controls displayed an extensive and intense
4+ positive combined nuclear and cytoplasmic staining.
All negative controls lacked cells displaying an immuno-
reaction. Except for one sentinel node metastasis, all
melanoma metastases displayed an elevated proliferative
index as shown by MIB-1 staining. Of melanoma
metastases, 8 showed an index in less than 10% of
melanoma cells; the index was 10–25% in 24 melanoma
metastases, and 25–50% in 13 melanoma metastases. Of
lymph-node nevi, 12 showed no proliferation while 5
showed a proliferative index of less than 0.3%. Three
sentinel-node metastases and one lymph-node nevus
could not be stained with Ki-67 because the lesion was
not present in additional serial sections. The detailed
results of immunohistochemical staining for p16 and Ki-
67 are shown in Table 1, Table 2 and Table 3.
Discussion
The differential diagnosis of lymph-node nevus and
melanoma metastasis becomes increasingly important in
the investigation of sentinel lymph nodes. It is, however,
Fig. 1 Nodal nevus (patient 3). A Cluster of melanocytes lacking
clear-cut atypia but extending into the lymph node parenchyma
(haematoxylin-eosin, 500). B Lack of immunostaining for HMB
45 (500). C Immunostaining for S-100 protein (250). D 3+
nuclear and cytoplasmic immunostaining for p16 (250)
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difficult to reliably distinguish lymph-node nevi from
metastases of melanoma using conventional histology.
This difficulty is partly due to the nevoid pattern of some
melanoma metastases, which may be devoid of clear-cut
atypical cells (Fig. 2) [5, 11, 12, 19, 21]. Even upon
comparing the primary with its metastasi(e)s, it is
sometimes less than obvious that the lymph-node lesion
represents a metastasis. The localisation within the
lymph-node capsule is an important diagnostic criterion
for the diagnosis of nodal nevi [2, 14]. However, this
criterion proves not to be entirely reliable, as melanoma
metastases are sometimes confined to the lymphatic space
adjacent to the lymph-node capsule (Fig. 2) and nodal
nevi may show parenchymal involvement [20]. The
demonstration of the expression of HMB 45 may be
helpful, although not entirely reliable, as a loss of HMB
Fig. 2 Melanoma metastasis in a sentinel-node biopsy (patient,
12b). A A small number of melanoma cells are confined to the
lymphatic space within the capsule and are not markedly atypical
(haematoxylin-eosin, 300). B S-100 protein immunostaining
(125). The melanoma cells are negative for HMB 45 (125; C)
and p16 (500; D). E A micrometastasis with identical morphology
in the parenchyma of the same lymph node confirms the diagnosis
of the presence of melanoma cells within the capsule. Lack of
immunostaining for p16 (250). F Haematoxylin-eosin (320). G
Immunostaining for S-100 protein (150)
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45 expression is reported in at least 20% of melanoma
metastases [4].
We demonstrated a clear-cut difference in the staining
pattern of p16 between lymph-node nevi and melanoma
metastases. Using immunohistochemistry, we found nu-
clear and cytoplasmic p16 staining in all nevi, indepen-
dent of their localisation (dermal or lymph node).
Furthermore, we have demonstrated the absence of
nuclear staining in 48 melanoma metastases, except for
1 skin metastasis, which displayed a weak nuclear
immunoreaction. However, a diffuse cytoplasmic staining
in the absence of nuclear staining was present in 13 of 49
melanoma metastases.
P16 immunohistochemistry often revealed a larger
extent of nodal nevi in comparison with tinctorial
staining. Sometimes small melanocyte groups are present
within the lymph-node capsule. They may, therefore, be
difficult to recognise, even upon using S-100 protein
immunohistochemistry, because—depending on the anti-
body used—they may be masked by dendritic cells
(Fig. 4). Nodal nevi were reported to occur from less than
1% of axillary nodes dissected for mammary carcinoma
[1, 17] up to 3.9% in sentinel lymph nodes of various
localisations of patients suffering from cutaneous mela-
noma [2]. Due to the aforementioned diagnostic difficul-
Fig. 3 Soft tissue metastasis of the axilla (patient 17, A) and
inguinal sentinel lymph-node metastasis (patient 8, B and C). A
Lack of immunostaining for p16 (250). Dermal nevus with 4+
nuclear and cytoplasmic immunostaining for p16 as positive control
(inset, 200). B Haematoxylin-eosin (200). C Weak cytoplasmic
staining in absence of nuclear immunostaining for p16 (200)
Fig. 4 Histology of a small cluster of intracapsular melanocytes. A
Melanocytes are masked by S-100 protein-immunostained dendritic
cells (35). B Some intracapsular melanocytes detected with 4+
nuclear and cytoplasmic immunostaining for p16, 35 (inset,
250). C Haematoxylin-eosin (400)
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ties, the real incidence of nodal nevi might be higher than
hitherto reported.
In some larger nevi, we found p16-positive cells
displaying co-expression of S-100 protein in the lymph-
node parenchyma. We, therefore, assume these cells to be
melanocytes. This finding adds support to the hypothesis
of the embolic origin of lymph-node nevi [2], which was
put forward in previous reports in which melanocytes
have been demonstrated to occur in the sinus of lymph
nodes [20]. A recent study [6] has noted a strong
association between nodal and cutaneous nevi.
A recent report showed that lack of MIB-1 staining or
a labelling index below 1% strongly favours nevus versus
melanoma metastasis [13]. This is consistent with our
assessment of the proliferation index in nevi and mela-
noma metastases. Unfortunately it may prove difficult or
impossible to precisely define a labelling index in very
small lesions.
We consider immunostaining for p16 an important
additional marker to differentiate nodal nevi from mel-
anoma metastases and, therefore, recommend its use
(Table 4).
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